Iqvia Holdings Inc (NYSE:IQV) – Stock analysts at William Blair decreased their Q1 2018 earnings per share (EPS) estimates for shares of Iqvia in a note issued to investors on Thursday. William Blair analyst J. Kreger now anticipates that the medical research company will post earnings per share of $0.69 for the quarter, down from their prior estimate of $1.24. William Blair also issued estimates for Iqvia’s Q2 2018 earnings at $0.71 EPS, Q3 2018 earnings at $0.79 EPS, Q4 2018 earnings at $0.94 EPS, FY2018 earnings at $3.13 EPS, FY2019 earnings at $3.85 EPS and FY2020 earnings at $4.77 EPS.
Several other equities analysts also recently commented on the company. Zacks Investment Research downgraded Iqvia from a “hold” rating to a “sell” rating in a research report on Tuesday. Royal Bank of Canada set a $118.00 target price on Iqvia and gave the company a “buy” rating in a research report on Thursday, February 15th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $103.00 target price on shares of Iqvia in a research report on Thursday, February 15th. JPMorgan Chase & Co. upped their target price on Iqvia from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Mizuho set a $97.00 target price on Iqvia and gave the company a “hold” rating in a research report on Wednesday, January 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $110.02.
Iqvia (IQV) opened at $101.72 on Monday. Iqvia has a 12-month low of $75.94 and a 12-month high of $110.67. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.19 and a quick ratio of 1.22. The company has a market capitalization of $21,160.00, a P/E ratio of 67.81, a PEG ratio of 1.81 and a beta of 0.61.
Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.34 by ($0.02). Iqvia had a net margin of 13.44% and a return on equity of 13.03%. The firm had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same period in the previous year, the company posted $1.09 EPS. Iqvia’s revenue for the quarter was up 10.7% compared to the same quarter last year.
In related news, insider Ari Bousbib sold 46,080 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $101.79, for a total transaction of $4,690,483.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total value of $999,700.00. The disclosure for this sale can be found here. Insiders have sold 8,727,078 shares of company stock worth $890,124,079 in the last three months. 6.40% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the stock. Halsey Associates Inc. CT acquired a new stake in Iqvia during the fourth quarter worth approximately $18,226,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in Iqvia during the fourth quarter worth approximately $11,695,000. MetLife Investment Advisors LLC bought a new stake in Iqvia during the fourth quarter worth $4,410,000. Jump Trading LLC bought a new stake in Iqvia during the fourth quarter worth $326,000. Finally, Pacific Grove Capital LP bought a new stake in Iqvia during the fourth quarter worth $5,163,000. 96.09% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://ledgergazette.com/2018/02/20/q1-2018-eps-estimates-for-iqvia-holdings-inc-iqv-cut-by-william-blair.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.